Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Eastell, R; Nickelsen, T; Marin, F; Barker, C; Hadji, P; Farrerons, J; Audran, M; Boonen, S; Brixen, K; Gomes, JM; Obermayer-Pietsch, B; Avramidis, A; Sigurdsson, G; Glüer, CC.
Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS).
J Bone Miner Res. 2009; 24(4): 726-736.
Doi: 10.1359/jbmr.081215
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Obermayer-Pietsch Barbara
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- It is unclear which treatment should be given after stopping teriparatide therapy for severe osteoporosis. In a prospective, randomized, controlled, 2-yr study, we compared BMD effects and clinical safety of three follow-up treatments (anabolic with teriparatide, antiresorptive with raloxifene, or no active treatment) after 1 yr of teriparatide. Postmenopausal women with osteoporosis and a recent fragility fracture received open-label teriparatide (20 microg/d) for 12 mo before they were randomized (3:1:1) to continue teriparatide (n = 305), switch to raloxifene 60 mg/d (n = 100), or receive no active treatment for the second year (n = 102). All patients received calcium and vitamin D supplementation. Changes in areal BMD from baseline to 24 mo were analyzed using mixed-model repeated measures. Daily teriparatide treatment for 2 yr significantly increased spine BMD by 10.7%. Patients receiving raloxifene in year 2 had no further change in spine BMD from year 1 (change from baseline, 7.9%), whereas patients receiving no active treatment had a BMD decrease of 2.5% in year 2 (change from baseline, +3.8%). At the total hip, BMD increases from baseline at 2 yr were 2.5% with teriparatide, 2.3% with raloxifene, and 0.5% with no active treatment; the respective changes at the femoral neck were 3.5%, 3.1%, and 1.3%. The study had insufficient power to assess antifracture efficacy. In conclusion, BMD increases progressively over 2 yr of teriparatide therapy in women with severe osteoporosis. After discontinuation of teriparatide, raloxifene maintains spine BMD and increases hip BMD.
- Find related publications in this database (using NLM MeSH Indexing)
- Bone Density - drug effects Bone Density - physiology
- Bone Density Conservation Agents - adverse effects Bone Density Conservation Agents - pharmacology Bone Density Conservation Agents - therapeutic use
- Cohort Studies -
- Drug Therapy, Combination -
- Europe -
- Female -
- Fractures, Bone - complications Fractures, Bone - drug therapy Fractures, Bone - physiopathology
- Humans -
- Middle Aged -
- Osteoporosis, Postmenopausal - chemically induced Osteoporosis, Postmenopausal - complications Osteoporosis, Postmenopausal - drug therapy Osteoporosis, Postmenopausal - physiopathology
- Teriparatide - adverse effects Teriparatide - pharmacology Teriparatide - therapeutic use
- Find related publications in this database (Keywords)
- BMD
- osteoporosis
- postmenopausal women
- raloxifene
- teriparatide